KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Receivables: 2017-2025

Historic Receivables for Moderna (MRNA) over the last 7 years, with Sep 2025 value amounting to $2.1 billion.

  • Moderna's Receivables fell 25.81% to $2.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $3.4 billion, marking a year-over-year decrease of 36.89%. This contributed to the annual value of $757.0 million for FY2024, which is 53.93% down from last year.
  • According to the latest figures from Q3 2025, Moderna's Receivables is $2.1 billion, which was up 542.99% from $321.0 million recorded in Q2 2025.
  • Over the past 5 years, Moderna's Receivables peaked at $3.2 billion during Q4 2021, and registered a low of $294.0 million during Q2 2023.
  • Its 3-year average for Receivables is $1.2 billion, with a median of $757.0 million in 2024.
  • In the last 5 years, Moderna's Receivables skyrocketed by 23,031.11% in 2021 and then crashed by 89.30% in 2023.
  • Quarterly analysis of 5 years shows Moderna's Receivables stood at $3.2 billion in 2021, then plummeted by 55.18% to $1.4 billion in 2022, then increased by 13.62% to $1.6 billion in 2023, then crashed by 53.93% to $757.0 million in 2024, then fell by 25.81% to $2.1 billion in 2025.
  • Its Receivables stands at $2.1 billion for Q3 2025, versus $321.0 million for Q2 2025 and $302.0 million for Q1 2025.